ÇòËÙÌåÓý

±±¾©»ùÒò×éËù£¨¹ú¼ÒÉúÎïÐÅÏ¢ÖÐÐÄ£©ÏàÖú½Òʾ¶ùͯ°×Ѫ²¡¸É/×æϸ°ûµÄÒìÖÊÐÔ¼°»¯ÁÆÄÍÒ©µÄ¸Éϸ°ûÑÇȺ

¡¡¡¡¼±ÐÔËèϵ°×Ѫ²¡£¨acute myeloid leukemia, AML£©ÊÇÒ»ÖÖ¶ñÐÔѪҺÖ×Áö £¬Í¨³£ÓÉÓÚËèϵÔìѪ¸É/×æϸ°ûÆÊÎöÊÜ×è¶øÒýÆð¡£AML²¡³Ì½øչѸËÙ¡¢ÖÎÓúÂʽϵÍ¡£¾Ýͳ¼Æ £¬¶ùͯ»¼ÕßµÄÎåÄêÎÞ²¡Éú´æÂʽöÔ¼50%¡ £»¯ÁÆÊÇAMLµÄÖ÷ÒªÖÎÁÆÒªÁìÖ®Ò» £¬ÄÜÏÔÖø¼õÉÙÖ×Áöϸ°ûÊýÁ¿ £¬Ê¹»¼Õߵִﻺ½â £¬µ«ÈÔÓÐһС²¿·ÖÖ×Áöϸ°û²ÐÁô £¬¿ÉÄܳÉΪÒýÆð¼²²¡¸´·¢µÄÖÖ×Ó¡£ËäÈ»»ùÓÚ»ùÒòÍ»±äµÄÒªÁì¿ÉÒÔÁéÃôµØ¼ì²â²ÐÁôϸ°û £¬µ«Òª½âÎö»º½âÆÚ²ÐÁôµÄ°×Ѫ²¡Ï¸°ûµÄÉúÎïѧÌØÐÔÈ´ÃæÁÙ¾Þ´óÌôÕ½¡£ÁÙ´²ÉÏҲһֱȱ·¦ÌØÒìÐÔµÄÒªÁìÓÃÓÚÕï¶Ï¡¢¼à²âºÍÇå³ýÕâЩϸ°û¡£

¡¡¡¡¾Û½¹ÓÚÉÏÊöÁÙ´²ÎÊÌâ £¬ÇòËÙÌåÓý£¨¹ú¼ÒÉúÎïÐÅÏ¢ÖÐÐÄ£©µÄÍõÇ°·ÉÍŶÓÓëËÕÖÝ´óѧÁ¥Êô¶ùͯҽԺµÄºúÉÜÑàÍŶÓÏàÖú £¬ÒÀÍÐÓÚ¶ùͯAMLµÍ¼ÁÁ¿»¯ÁÆÁªºÏG-CSFÈýÆÚËæ»ú±ÈÕÕ¶àÖÐÐÄÁÙ´²ÊÔÑé(CALS III-AML18) £¬Í¨¹ý¾«Ï¸½âÎö»¼Õß»¯ÁÆÇ°ºó¹ÇËèµÄÒìÖÊÐÔϸ°ûȺÌå £¬²¢½áºÏÁÙ´²´óÑù±¾ÐÐÁÐÑéÖ¤ºÍ¹¦Ð§ÊµÑé £¬Ê״ο̻­Á˶ùͯAML»¯Áƺó²ÐÁôÖ×Áöϸ°ûµÄµ¥Ï¸°ûת¼×éͼÆס£¸ÃÑо¿Ã÷È·ÁË»¼ÕßÌåÄڵİ×Ѫ²¡¸Éϸ°û£¨leukemia stem cell, LSC£©ºÍÑõ»¯Á×Ëữ(oxidative phosphorylation, OXPHOS)Á½¸öÄÍÒ©ÌØÕ÷¼°Æä¶ÔÓ¦µÄ¾«È·Ï¸°ûÑÇȺ £¬·¢Ã÷ÁËÄÍÒ©µÄHSC-like¸Éϸ°ûÑÇȺ¼°ÆäÍâò±ê¼ÇÎïCD69 £¬²¢¿ª¶Ë½ÒʾÁËCD69ͨ¹ýµ÷¿ØmTOR-CCND1-CXCR4Öá½éµ¼ÄÍÒ©µÄ·Ö×Ó»úÖÆ¡£Ñо¿»¹·¢Ã÷¸Ã¸Éϸ°ûÄÍÒ©ÑÇȺµÄϸ°û±ÈÀý¸ßÓëÔ¤ºó²»Á¼µÄÁÙ´²±íÐͺͻùÒò×éÌØÕ÷Ïà¹Ø¡£ÕâЩÈÏʶΪÁÙ´²Õï¶ÏºÍ¼à²âÌṩÁËÖØÒªµÄÀíÂÛÒÀ¾Ý¡£¸Ã½á¹ûÒÔ¡±Single-cell transcriptomics reveals multiple chemoresistant properties in leukemic stem and progenitor cells in pediatric AML¡±ÎªÌâ £¬ÓÚ2023Äê8ÔÂ31ÈÕÐû²¼ÔÚGenome Biology ÆÚ¿¯¡£

¡¡¡¡ÇòËÙÌåÓý£¨¹ú¼ÒÉúÎïÐÅÏ¢ÖÐÐÄ£©ÍõÇ°·ÉÑо¿Ô±¡¢ËÕÖÝ´óѧÁ¥Êô¶ùͯҽԺµÄºúÉÜÑàÖ÷ÈÎΪ±¾ÎĵÄÅäºÏͨѶ×÷Õß £¬ÇòËÙÌåÓý£¨¹ú¼ÒÉúÎïÐÅÏ¢ÖÐÐÄ£©²©Ê¿½áÒµÉú½­æ­æú͸±Ñо¿Ô±ºÍ·òºì £¬ÒÔ¼°ËÕÖÝ´óѧÁ¥Êô¶ùͯҽԺ²©Ê¿½áÒµÉúÕÅÓÀƽºÍ²©Ê¿ºóÌï԰԰ΪÎÄÕµÄÅäºÏµÚÒ»×÷Õß¡£¸ÃÑо¿»ñµÃÁ˿Ƽ¼²¿ÖصãÑз¢¼Æ»®¡¢¹ú¼Ò×ÔÈ»¿Æѧ»ù½ð¡¢½­ËÕÊ¡¡¢ÇòËÙÌåÓýµÈÏîÄ¿µÄ×ÊÖú¡£

welcome-ÇòËÙÌåÓý

¶ùͯ°×Ѫ²¡¸É/×æϸ°ûµÄÒìÖÊÐÔ¼°»¯ÁÆÄÍÒ©µÄ¸Éϸ°ûÑÇȺ

¡¡¡¡ÂÛÎÄÁ´½Ó

¸½¼þÏÂÔØ£º
ÍøÕ¾µØͼ